Computational Modelling Suggests Bacteriostatic Saline Does Not Reverse Botulinum Toxin-Induced Brow Ptosis

Area of Science:

• Pharmacology
• Toxicology
• Computational Biology

Background:

• Anecdotal reports suggest bacteriostatic saline (BS) can reverse botulinum toxin type A (BoNTA) effects.
• This claim challenges the understanding of BoNTA's irreversible SNAP-25 cleavage and intracellular persistence.

Purpose of the Study:

• To evaluate the hypothesis that BS can reverse BoNTA-induced brow ptosis.
• To investigate the pharmacokinetic/pharmacodynamic (PK/PD) mechanisms underlying BoNTA recovery and potential BS interaction.

Main Methods:

• Utilized high-resolution PK/PD modeling on the AesthetiSim™ platform with 30,000 virtual patients.
• Simulated BoNTA alone, BoNTA followed by BS, or BoNTA followed by normal saline (NS) at Day 7.
• Incorporated BoNTA diffusion, internalization, SNAP-25 cleavage, neuromuscular output, and BS effects on membrane permeability and endosomal trafficking.

Main Results:

• BS group showed faster partial reactivation (T30) and a 6.5-day reduction in time to 80% muscle force recovery (T80) (p < 0.001).
• BS increased the area under the effect curve by 9.7%, indicating slightly enhanced overall muscle function.
• Molecular simulations showed minimal impact of benzyl alcohol (BnOH) on BoNTA-SNAP-25 binding affinity; intracellular light chain degradation was the primary recovery driver.

Conclusions:

• Bacteriostatic saline does not pharmacologically reverse botulinum toxin type A's molecular action.
• BS may transiently influence recovery kinetics through non-receptor-mediated pathways, but not to the extent of a true reversal.
• Emphasizes the need for mechanistic scrutiny of rapid-reversal claims, especially those lacking biological plausibility.